ANTX
AN2 Therapeutics, Inc.
Biotechnology
Market Cap$130M
5Y Perf.-68.5%
Build Your Comparison
Side-by-side financial analysisANTX
PRAX
Try popular comparisons:
Stock Comparison
ANTX vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.70B
5Y Perf.+74.0%
ANTX vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ANTX |  PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $130M | $7.70B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-35M | $-327M |
| Total Debt | $0.00 | $110K |
| Cash & Equiv. | $20M | $357M |
ANTX vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANTX
PRAX
| Stock | Mar 22 | Jun 26 | Return |
|---|---|---|---|
| AN2 Therapeutics, I… (ANTX) | 100 | 31.5 | -68.5% |
| Praxis Precision Me… (PRAX) | 100 | 174.0 | +74.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANTX vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANTX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Praxis Precision Medicines, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ANTX emerged as the overall leader. Track its performance:
ANTX
AN2 Therapeutics, Inc.
The Income Pick
ANTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.42
- EPS growth 32.6%
- Lower volatility, beta 0.42, current ratio 6.87x
Best for: income & stability and growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX is the clearest fit if your priority is long-term compounding.
- -36.1% 10Y total return vs ANTX's -39.4%
- +491.9% vs ANTX's +319.5%
- -40.2% ROA vs ANTX's -47.3%, ROIC -65.0% vs -61.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ANTX | 189.3% revenue growth vs PRAX's -100.0% |
| Quality / Margins | ANTX | 4.7% margin vs PRAX's 2.4% |
| Stability / Safety | ANTX | Beta 0.42 vs PRAX's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  PRAX | +491.9% vs ANTX's +319.5% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs ANTX's -47.3%, ROIC -65.0% vs -61.1% |
ANTX vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ANTX vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGANTX
ANTXAN2 Therapeutics, Inc.
1leads
PRAXPraxis Precision Medi…
2leads
6 Total Categories
CATEGORYLEADERvs ANTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ANTX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ANTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ANTX and PRAX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$37M | -$357M |
| Net IncomeAfter-tax profit | -$35M | -$327M |
| Free Cash FlowCash after capex | -$31M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +17.1% | +2.7% |
ANTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ANTX and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $130M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $110M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -4.09x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.70x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ANTX and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-52 for ANTX. On the Piotroski fundamental quality scale (0–9), PRAX scores 3/9 vs ANTX's 1/9, reflecting mixed financial health.
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -52.3% | -43.0% |
| ROA (TTM)Return on assets | -47.3% | -40.2% |
| ROICReturn on invested capital | -61.1% | -65.0% |
| ROCEReturn on capital employed | -56.4% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$20M | -$357M |
| Cash & Equiv.Liquid assets | $20M | $357M |
| Total DebtShort + long-term debt | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
PRAX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,580 today (with dividends reinvested), compared to $3,078 for ANTX. Over the past 12 months, PRAX leads with a +491.9% total return vs ANTX's +319.5%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs ANTX's -13.1% — a key indicator of consistent wealth creation.
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | +327.0% | -6.9% |
| 1-Year ReturnPast 12 months | +319.5% | +491.9% |
| 3-Year ReturnCumulative with dividends | -34.4% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -69.2% | -14.2% |
| 10-Year ReturnCumulative with dividends | -39.4% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -13.1% | +164.8% |
PRAX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ANTX and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ANTX is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs ANTX's 68.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.42x | 1.55x |
| 52-Week HighHighest price in past year | $6.91 | $366.52 |
| 52-Week LowLowest price in past year | $1.00 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +68.6% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 54.5 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 261K | 396K |
Evenly matched — ANTX and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANTX as "Buy" and PRAX as "Buy". Consensus price targets imply 127.8% upside for PRAX (target: $607) vs 89.9% for ANTX (target: $9).
| Metric | ANTXAN2 Therapeutics,… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $607.15 |
| # AnalystsCovering analysts | 8 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ANTX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 2 of 6 categories
Loading custom metrics...
ANTX vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANTX or PRAX a better buy right now?
Analysts rate AN2 Therapeutics, Inc.
(ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANTX or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -14. 2%, compared to -69. 2% for AN2 Therapeutics, Inc. (ANTX). Over 10 years, the gap is even starker: PRAX returned -36. 1% versus ANTX's -39. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANTX or PRAX?
By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.
(ANTX) is the lower-risk stock at 0. 42β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 268% more volatile than ANTX relative to the S&P 500.
04Which is growing faster — ANTX or PRAX?
On earnings-per-share growth, the picture is similar: AN2 Therapeutics, Inc.
grew EPS 32. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANTX or PRAX?
AN2 Therapeutics, Inc.
(ANTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANTX leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — ANTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANTX or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANTX or PRAX better for a retirement portfolio?
For long-horizon retirement investors, AN2 Therapeutics, Inc.
(ANTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42)). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANTX: -39. 4%, PRAX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANTX and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.